Abstract 106: Validation Of The Unruptured Intracranial Aneurysm Treatment Score (UIATS) to Guide Management of Unruptured Intracranial Aneurysms
Objective: We previously derived the Unruptured Intracranial Aneurysm Treatment Score (UIATS), designed using a multidisciplinary consensus approach among neurovascular specialists from diverse geographic and practice backgrounds. Here, we report on the development and validation of the final version of UIATS.
Method: An international, multidisciplinary (neurosurgery, neuroradiology, neurology, clinical epidemiology) group of 69 (39 panel members and 30 blinded external reviewers) specialists in the research and treatment of UIAs was convened. A web survey-based Delphi consensus process consisting of 7 rounds was utilized to rate numerous features of potential relevance in the assessment and treatment of UIAs and to develop the UIATS. Mean ratings were repeatedly used to determine statistical weight for each factor and then transformed into corresponding scores for every item to create the UIATS. For internal and blinded external validation, 30 representative cases of patients with UIAs were used to test the level of agreement (5 point Likert Scale) with treatment recommendations based on the UIATS.
Results: The final UIATS system was designed in three domains (patient-, aneurysm - and treatment-related), comprising 13 different categories and 29 different features (Figure 1). Mean agreement based on Likert scores (5 indicating strong agreement and 1 indicating strong disagreement) was 4·2 for both reviewer cohorts, whereas mean agreement per case was 4·2 (panel members) and 4·5 (external reviewers) (p=0·017, Mann-Whitney-U Test).
Conclusion: The final version of UIATS system was internally and externally validated by a large multidisciplinary group of neurovascular specialists, which suggests that the UIATS reflects contemporary decision-making regarding management of a patient with an UIA. The UIATS may aid clinicians in deciding on the appropriate management for an UIA.
Author Disclosures: N. Etminan: None. R.D. Brown: None. K. Beseoglu: None. S. Juvela: None. A. Morita: None. J.C. Torner: None. J. Raymond: None. C.P. Derdeyn: Ownership Interest; Modest; Pulse Therapeutics. Consultant/Advisory Board; Modest; Microvention, Penumbra, Silk Road, Pulse Therapeutics. A. Raabe: None. J. Mocco: None. A. Abdulazim: None. M. Korja: None. E. Connolly: None. H. Steinmetz: None. G. Lanzino: None. A. Pasqualin: None. D. Rüfenacht: None. P. LeRoux: None. P. Vajkoczy: None. C. McDougall: None. D. Hänggi: None. G.J.E. Rinkel: None. R. Macdonald: None.
- © 2015 by American Heart Association, Inc.